KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

NovoCure (NVCR) EBIT Margin (2016 - 2025)

Historic EBIT Margin for NovoCure (NVCR) over the last 12 years, with Q3 2025 value amounting to 21.54%.

  • NovoCure's EBIT Margin fell 8500.0% to 21.54% in Q3 2025 from the same period last year, while for Sep 2025 it was 27.51%, marking a year-over-year decrease of 100.0%. This contributed to the annual value of 28.17% for FY2024, which is 175500.0% up from last year.
  • As of Q3 2025, NovoCure's EBIT Margin stood at 21.54%, which was down 8500.0% from 24.89% recorded in Q2 2025.
  • In the past 5 years, NovoCure's EBIT Margin ranged from a high of 0.07% in Q1 2021 and a low of 49.71% during Q2 2023
  • Its 5-year average for EBIT Margin is 24.61%, with a median of 22.33% in 2024.
  • In the last 5 years, NovoCure's EBIT Margin plummeted by -487200bps in 2023 and then surged by 273800bps in 2024.
  • NovoCure's EBIT Margin (Quarter) stood at 17.56% in 2021, then tumbled by -91bps to 33.46% in 2022, then decreased by -16bps to 38.66% in 2023, then fell by -2bps to 39.25% in 2024, then soared by 45bps to 21.54% in 2025.
  • Its EBIT Margin stands at 21.54% for Q3 2025, versus 24.89% for Q2 2025 and 24.43% for Q1 2025.